Latest Breaking News On - Hematopoietic malignancies program - Page 1 : comparemela.com

New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating.

United statesCiltacabtagene autoleucelObrian kenneyThomas martinSen zhuangJessica mooreSatu glaweMyeloma programJanssen biotech incAmerican society of clinical oncologyJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyClinical researchAmerican cancer society

Janssen: New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma

Data presented at ASH 2021 congress show 83 percent of patients achieved a stringent complete response at median follow-up of 22 months1 92 percent of evaluable patients achieved minimal residual

United statesCiltacabtagene autoleucelNoah reymondEdmond chan mbchThomas martinSen zhuangJessica mooreMyeloma programJanssen biotech incAmerican society of clinical oncologyAmerican society of hematology annual meetingJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyClinical research

New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating.

United statesCiltacabtagene autoleucelObrian kenneyThomas martinSen zhuangJessica mooreSatu glaweMyeloma programJanssen biotech incAmerican society of clinical oncologyJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyClinical researchAmerican cancer society

FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalSouth koreaSan franciscoEva schaefer jansenSuzanne grecoArnaud delepineFelix lauscherThomasg martinFara berkowitzPeterc adamsonKd sarclisaSally bainEuropean hematology association virtual congressUniversity of californiaMyeloma program

Sanofi: FDA approves Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Sanofi: FDA approves Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.